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Erdheim-Chester Disease (ECD) is a rare form of non Langerhans' cell histiocytosis. Individuals affected by this
disease are typically adults between their 5th and 7th decades of life. Males and females are almost equally
affected. The multi systemic form of ECD is associated with significant morbidity, which may arise due to histiocytic
infiltration of critical organ systems. Among the more common sites of involvement are the skeleton, central
nervous system, cardiovascular system, lungs, kidneys (retroperitoneum) and skin. The most common presenting
symptom of ECD is bone pain. The etiology of ECD is unknown yet thought to be associated with an intense TH1
immune response. It may also be associated with the V600E BRAF mutation, as described in as many as half of the
patients in recent studies. Bilateral symmetric increased tracer uptake on 99mTc bone scintigraphy affecting the
periarticular regions of the long bones is highly suggestive of ECD. However, definite diagnosis of ECD is
established only once CD68(+), CD1a(−) histiocytes are identified within a biopsy specimen. At present, this obscure
ailment embodies numerous challenges to medical science. Given its rarity, it is diagnostically elusive and requires a
high level of clinical suspicion. Therapeutically, it is of limited alternatives. Currently, interferon-α is the most
extensively studied agent in the treatment of ECD and serves as the first line of treatment. Treatment with other
agents is based on anecdotal case reports and on the basis of biological rationale. Nevertheless, cladribine (2CDA),
anakinra and vemurafenib are currently advocated as promising second line treatments for patients whose
response to interferon-α is unsatisfactory. Overall, the 5 year survival of ECD is 68%. Herein, the authors mustered
and brought about a panoramic consolidation of all the relevant facts regarding ECD. This work highlights the
different clinical, radiological and pathological manifestations associated with ECD, the differential diagnoses, the
various treatment options and the acknowledged science explaining the disease.
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History, Classification, Epidemiology, Etiology and
Prognosis
Erdheim-Chester Disease (ECD) is a rare form of non
Langerhans' cell histiocytosis originally described as "Lipid
Granulomatosis" in 1930 by Jakob Erdheim and William
Chester. As of present time, only several hundred cases
had been documented in the medical literature [1], the
majority of which were described in the past ten years [2].
The chronicles of the disease encompass a variety of patho-
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stated.originating from the infiltration of lipid-laden histiocytes
with foamy or eosinophilic cytoplasm to bones and various
organs. The heterogeneous manifestations of ECD vary
amongst different individuals. This results in a presentation
that may vary from an indolent focal disease to a life
threatening organ failure [3]. Although ECD primarily
affects adults between their 5th and 7th decades of life
[4] patients have been diagnosed between the ages of 7 to
84 years [5] and pediatric cases have been documented in
the medical literature [6-9]. A slight male predominance
was noted amongst patients [10] and some studies suggest
that male patients are diagnosed at a more advanced age
than female patients [11]. The etiology of the disease is
unknown [12] and considered to be non-genetic and not
associated with an infectious agent [11,13]. The scarcity of
patients serves as an obstacle in medical science's endeavortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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mulation of controlled randomized trials - impossible.
Researchers face a constant shortage of relevant biological
samples. Despite recent advancements, the pathogenesis
of this disease is still poorly understood. The broad and
complex manifestations of ECD, in conjunction with its
rarity and with only a handful of centers of referral in the
world may inevitably lead to misdiagnosis. Physicians
mainly rely on retrospective data describing the clinical
course of the disease as published in former case reports
and literature reviews. Consequently, current treatments
are based on an anecdotal evidence base and the overall
prognosis is grim. Arnaud et al. [1] report of the 1-year
and 5-year survival rates to be 96% and 68% respectively.
Many academic debates had risen in the past concerning
the proper classification of ECD. Initially, it was thought
to be a variant of Langerhans' Cell Histiocytosis (LCH)
[14,15] and as time went by, ECD developed a unique
identity as a singular disease entity in the medical litera-
ture, baring specific diagnostic criteria. When referring to
histiocytic disorders, it is comfortable to classify them into
Langerhans' Cell Histiocytoses (or "X Type" Histiocytoses)
and Non-Langerhans Cell Histiocytosis (or "Non X Type"
HIstiocytoses). While the former includes diseases such as
Hand-Schuller-Christian disease, Letterer-Siwe disease, and
eosinophilic granuloma [5], the latter includes diseases
such as Erdheim-Chester disease (ECD) [5] and Juvenile
xanthogranuloma (JXA) [16]. In respect to the above, one
cannot ignore the common properties of histiocytic disor-
ders in general and of LCH and ECD in particular. Present
knowledge of the pathogenesis and etiology of ECD is very
little, much is unknown and many questions remain un-
answered. Interesting tangency points between LCH
and ECD exist [17,18] both diagnostically and therapeutic-
ally, suggesting a common denominator of both conditions.
This fact is even more substantiated in the face of patients
diagnosed with both diseases at the same time [19-23].
Diagnostic criteria
Diagnosis of ECD relies on established radiological and
histological criteria. The major criterion is the distinct
histological pattern that characterizes the condition [24]
which is usually obtained after the radiological findings,
which in turn are prompted by the patient’s symptoms.
Thus, typical histological findings are sufficient to confirm
ECD. Considering the rarity of this condition, the necessity
for a pathognomonic signature of the disease seems
abundantly clear. The most common presenting symptom
of ECD is bone pain. When submitting the absolute ma-
jority of ECD patients to imaging studies, characteristic
radiographic changes in the long bones appear (Figure 1).
These changes, namely, bilateral cortical sclerosis involving
the diametaphyseal regions, are considered virtually path-
ognomonic [25]. Two relevant types of imaging studies areradiographs and 99mTc bone scintigraphs. In ECD, bilateral
symmetric osteosclerotic lesions are typically observed on
radiographs, while abnormally strong labeling of the distal
ends of the long bones are observed on 99mTc bone
scintigraphs. Detecting either of those comprises the
radiological diagnostic criterion. The histological diag-
nostic criterion is met providing that typical ECD histio-
cytes are found in the examined lesion. These histiocytes
are non langerhans' foamy histiocytes, which lack Birbeck
granules, nested within a polymorphic granuloma, fibrosis
or xanthogranulomatosis. Immunohistochemical staining
is positive for CD68 and negative for CD1a [26]. Further
elaboration on the microscopic, ultrastructure and immuno-
histochemical properties of the typical histological findings
appear in Table 1.
General symptoms
A variety of general symptoms may accompany ECD.
These are relatively unspecific and do not appear globally
in all patients. However, when apparent, they may serve as
means for evaluating the patient’s well being and provide
gross assessment of the patient’s response to treatment.
Amongst them are fever, weakness, weight loss [5] and night
sweats [27]. Fatigue may be associated with a microcytic
anemia, which occasionally accompanies ECD [28]. Add-
itionally, pediatric cases of ECD may present with a failure
to thrive [9].
Skeletal involvement
Involvement of the skeleton occurs in up to 96% of ECD
patients. Bone pain, however, occurs in only 50% of the
cases [2]. The most frequently affected bones are the
femur, tibia and fibula and less frequently the ulna, radius
and humerus. Bone pain usually manifests around the
knees and ankles. Osteosclerosis occurs bilaterally and
symmetrically in the diametaphyseal regions of the long
bones. The axial skeleton and epiphyseal regions are usu-
ally spared [29]. However, Dion et al. [30] reported partial
epiphyseal involvement and evidence of periostitis upon a
thorough radiological survey of 11 ECD patients. While
the classical hallmark of the skeletal involvement of ECD
is osteosclerosis, occasionally, mixed sclerotic and lytic
lesions have been described. It is imperative to recognize
that bone lesions found in LCH are rather lytic than scler-
otic [31] further complicating the diagnosis in cases which
the typical bone changes are a tad less typical, in conjunc-
tion with osteolytic lesions. In their retrospective study
encompassing 59 cases of ECD in 1996, Veyssier-Belot
et al. reported that 5%-8% of the patients in the study also
had lytic lesions, either on the flat bones, like the ribs and
skull, or on the long bones [5]. On 2002, Oweity et al.
reported that 30% of ECD cases exhibit osteolytic lesion
involvement [13]. In addition, both typical and atypical
ECD lesions may present in atypical foci [32,33]. Both the
Figure 1 Diagnostic imaging in ECD. Various modalities in the skeletal assessment of a single ECD patient. (A) A plain radiograph of the
knees demonstrating bilateral sclerotic changes in the femoral and tibial bones. (B) 99mTc bone scintigraph taken prior to the diagnosis of ECD.
Note the abnormally increased tracer uptake especially involving the periarticular region of the femurs and the tibiae. (C) Coronal reconstruction
of a computed tomography study of the femurs and tibiae. Note the diffuse, irregular intra-medullary lytic-sclerotic pattern as well as the marked
cortical thickening of the tibiae. (D) Coronal reconstruction of a positron emission tomography taken for the purpose of follow up 4.5 years
pursuant the diagnosis of ECD. This study shows bilateral symmetric abnormally increased intra-medullary uptake of fluorodeoxyglucose in the
femurs and tibiae.
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related osseous involvement should be considered in the
differential diagnosis alongside other medical conditions -
on a case by case basis. These include osteomyelitis,
Paget's disease, lymphoma, sarcoidosis, bony metastases
[33] and lipid storage diseases such as Gaucher's disease
and Niemann-Pick disease [34]. The skeletal involvement
seldom appears alone. The retrospective study of 59 ECD






(*) Pathological confirmation of CD68(+), CD1a(−) histiocytes is both sufficient and mECD patients had extraskeletal manifestations upon diag-
nosis [5]. Moreover, Arnaud et al. recently reported that
98% of the 53 patients they reviewed had at least one
extraskeletal manifestation of the disease [1]. In summary,
the diagnosis of ECD is usually made on the basis of bone
pain and pathognomonic radiological features. However, it
may turn challenging due to the abundance of possible
extraskeletal involvement sites. Particularly in cases in
which the patient’s chief complaints deviate the physician’sBilateral symmetric diametaphyseal osteosclerosis of long bones
Symmetric and abnormally strong 99mTc labeling of the distal
ends of the long bones
Non Langerhans histiocytes with foamy or eosinophillic cytoplasm,
polymorphic granulomae and fibrosis, xanthogranulomatosis,
proliferating fibroblasts, lymphocytic aggregates, Touton giant cells
CD68(+), CD1a(−), S-100(negative/low)*
Lack of Birbeck granules
andatory for the diagnosis of ECD.
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disease.Central nervous system involvement
Progression of ECD to the CNS and adjacent structures,
such as the meninges, facial bones, orbits and intracranial
vasculature can manifest in a wide range of symptoms. The
location, size and nature of the lesion at hand determine
whether the patient will be completely asymptomatic, suffer
from various neurological deficits, severe disability or
succumb to his disease. CNS involvement appears in
approximately 51% of ECD patients and accounts for 29%
of all deaths, as reported by Arnaud et al. [1]. In another
retrospective analysis of 33 patients with confirmed ECD,
performed by Drier et al., 45% of the patients had symp-
toms related to CNS and/or orbital manifestations at
presentation. These manifestations, by order of frequency,
were diabetes insipidus, exophthalmos, cerebellar ataxia,
panhypopituitarism and papilledema [10]. The manifesta-
tions mentioned above correlate with diverse radiological
and pathological findings: involvement the hypothalamic-
pituitary axis where nodular or micronodular masses of
the infundibular stalk may be present, retro-orbital masses,
involvement of the dentate area of the cerebellum and
meningeal lesions of the dura. Other involvements reported
in the literature include thickening of the bones of the face
and skull, intracranial peri-arterial infiltration, intraluminal
involvement of the superior sagittal sinus [10], involvement
of the choroid plexus [35] and masses involving the
cerebral hemispheres. However, clinically evident deficits
in cerebral function are less common [13]. Any type of
lesion rarely appears alone; about 66% of the patients
examined by Drier et al. had simultaneous involvement of
at least two anatomical sites. An association was noted
between facial bone osteosclerosis and orbital or meningeal
masses. This could serve to direct the physician towards
the diagnosis of ECD in the appropriate settings. Lumbar
puncture is not recommended since ECD histiocytes rarely
appear in the cerebrospinal fluid [36]. The differential
diagnosis of ECD related intracranial lesions is wide: Intra-
cerebral histiocytic lesions may mimic a neoplasm of glial
origin [37]. Lesions of the cerebellum and brainstem may
appear similar to demyelinating diseases such as multiple
sclerosis [38]. ECD related suprasellar lesions should be
considered in the differential diagnosis alongside Langer-
hans cell histiocytosis or other adenomatous, granulomatous
or inflammatory processes of this region [3]. ECD related
retro-orbital involvement may resemble the retro-orbital
involvement seen in Wegener’s granulomatosis [10]. In
the appropriate clinical settings, Graves disease, Lang-
erhans cell histiocytosis, lymphoma, sarcoidosis, and
Sjogren’s disease should also be considered in this context
[10,39]. An ECD meningeal lesion may be mistaken for ameningioma [10,40,41] and ECD sinonasal lesions may
mimic rhinoscleroma [42].
Central diabetes insipidus is the most common of all
CNS manifestations in ECD. It should be noted that
histiocytosis associated diabetes insipidus appears early
in the natural history of these diseases in general and in
ECD in particular [43]. In some cases, even a decade or
longer passes before establishing a diagnosis [13] and thus,
a high level of suspicion is required. Hypopituitarism and
hyperprolactinemia may follow ECD associated dysfunction
of the hypothalamus-pituitary axis as well. It is hypothe-
sized that hyperprolactinemia results from mechanical
disruption of the hypothalamic dopaminergic prolactin
inhibiting pathway, possibly due to compromise of the
hypothalamo-pituitary portal system. Hypopituitarism
may manifest in different ways, including disruption of
thyroid function and gonadotropin balance. In all these
cases, MRI may demonstrate a mass in the pituitary stalk
or an absence of signal of the posterior pituitary on T1
weighted images. Upon a histological examination of the
anterior pituitary, prolactin cell hyperplasia may appear
in the adenohypophysis of patients with disseminated
ECD [3].
ECD related retro-orbital lesions may present bilaterally
or unilaterally, extraconal or intraconal. Most cases
however are bilateral and intraconal [10]. These lesions
may manifest clinically as exophthalmos. Osteosclerosis of
the facial bones commonly presents among ECD patients
with orbital lesions or with meningeal lesions. Orbital
lesions typically lack signal intensity on both T1 and T2
weighted MR images. Mass effect of the retro-orbital
lesions might result in thickening and tortuosity of the
optic nerves. The lacrimal glands and orbital muscles, as
well as the retro-orbital adipose tissue may be involved
with the lesions. Also, periorbital cutaneous xanthomas of
yellowish color may appear [39,44].
ECD associated cerebellar syndrome can develop over
several years [45]. Additionally, unlike most intracranial
lesions, cerebellar lesions appear to have no mass effect.
Histological examination of these lesions reveals extensive
loss of myelin sheath with gliosis and marked sparing of
axons [37,46]. A variety of symptoms correlate with brain-
stem and cerebellar involvement of ECD. Among them
are ataxia, pyramidal syndrome [10,28], cerebellar dysarth-
ria, multidirectional nystagmus, cerebellar dysmetria,
hypermetric saccades, negative suppression of the vestibulo-
ocular reflex [47] and dysdiadochokinesis [45]. On MRI,
these lesions typically appear to be characterized by high
signal intensity on T2 weighted images, low signal intensity
on T1 weighted images and no enhancement pursuant
administration of contrast material [10,23,47].
Drier et al. reported the existence of intracranial peri-
arterial lesions in approximately 10% of the ECD patients
they had reviewed. As noted before, the lesion-symptom
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lesion does not necessarily translate into a symptom.
However, one cannot ignore the possible ischemia and\or
thromboembolic complications which may theoretically
accompany such a lesion. Therefore, it is recommended to
closely monitor such lesions [10].
Cardiac involvement
Much like ECD involvement of the CNS, cardiovascular
involvement of the disease confers a reduced response to
treatment and an overall poor prognosis [48]. Approxi-
mately 75% of ECD patients suffer from cardiovascular
manifestations and about 60% of them will perish due to
cardiac complications [49]. The cardiovascular patterns
evident in ECD vary depending on the location and size of
the lesions. These lesions account for various clinical con-
sequences - congestive heart failure, myocardial infarction,
thromboembolism, cardiac remodeling, valvular dysfunc-
tion, ischemia, peripheral edema and others. Pericardial
infiltration is the most frequent cardiac manifestation of
ECD [50]. Both aortic and pericardial involvements of
ECD are seen well on computed tomography and echocar-
diography. Pericardial involvement in ECD takes several
forms and symptoms are correlated with the type, extent
and severity of the discussed involvement. Upon inspection
of the imaging studies, a thickened pericardium may appear
with or without an envelope of fibrosis. Pericarditis can
be identified by transthoracic echocardiography. A buildup
of percardial effusion may lead to cardiac tamponade. This
may be relieved by pericardiocentesis which bares diagnos-
tic and therapeutic purposes. Aggressive interventions may
include placement of a pericardial window, pericardectomy
and placement of a pericardial-abdominal shunt. In
one case a notable pericardial effusion in ECD has been
reported to mimic a disseminated malignancy [51]. A
cytological examination of the pericardial effusion may
reveal mesothelial cells, histiocytes and inflammatory cells.
A histological examination of a pericardial sample may
reveal infiltration of foamy histiocytes [52]. Myocardial
involvement follows the pericardial involvement in fre-
quency and presents mainly with myocardial hypertrophy
and thickening. This can be seen on echocardiography.
Among the different sites of myocardial involvements are
the ventricular walls, atrial walls, coronary sulcus [52] and
interatrial septum [53]. Involvement of the right atrium
with pseudo-tumoral infiltration and involvement of the
auriculoventricular sulcus were found at high frequencies
[54]. A case series reviewed by Haroche et al. included six
patients who presented with a right atrial tumor. In some
of the cases reported in the literature, the right atrial
tumor was found to traverse the entire atrial wall from the
endocardium to the epicardium, thus, disrupting normal
cardiac function. It appears that this particular process
begins in the subepicardial fatty tissue and progressesinto the myocardium. The differential diagnosis of an ECD
associated cardiac tumor includes mainly a cardiac myx-
oma [55]. In an article discussing the myocardial involve-
ment of ECD, Loeffler et al. stress that atrial myocardial
involvement in ECD should be recognized as a significant
contributor to the patient's morbidity [56]. Infiltration of
the myocardium by histiocytes and multi-nucleated giant
cells are probable biopsy findings in these cases. The
valvular involvement of ECD has been known to cause
mainly aortic and mitral regurgitation, preceding the
cardiac and hemodynamic consequences and natural
history of such insufficiencies [49,57]. Both an MRI and a
gated CT scan of the heart are valuable tools in assessing
cardiovascular involvement in ECD [54]. Among the ECD
related ECG abnormalities observed were short PR
segments, sinoauricular blocks, sinus bradycardia, MI
compatible Q wave abnormalities with no past MI, ST-T
abnormalities and a slight ST elevation [54].
Coronary & great vessels involvement
Perivascular infiltration in general and periaortic fibrosis
specifically, are among the most frequent cardiovascular
lesions in ECD and often worsen the prognosis [10].
Periaortic fibrosis appears as a "coated aorta" on CT scans.
The degree of periaortic fibrosis alters between patients
and anatomical locations. The lesion described can be
symmetric or non symmetric, circumferential or non
circumferential. It can be limited to a specific segment
of the aorta or affect the entire vessel. The "coated
aorta" phenomenon is the result of a periaortic infiltration
by histiocytes, predominantly to the adventitia. However,
it was also suggested that in some cases ECD histiocytes
infiltrate as deep as the intimal layer of the aorta. This is
not common, but further substantiated by an irregular ap-
pearance of the intima on CT among certain ECD patients
with aortic involvement - a finding that is so far pathogno-
monic to ECD [52]. The differential diagnosis of a "coated
aorta" appearance on CT includes retroperitoneal fibrosis
and Takayasu arteritis. Thus, such a CT finding should
prompt a bone scan which might be helpful in substantiat-
ing a diagnosis of ECD [58]. Perivascular infiltration is not
limited only to the aorta, as it has been identified in large
vessels adjacent to the aorta, including but not limited to
the brachiocephalic trunk, left common carotid artery, left
subclavian artery, coronary arteries, pulmonary trunk,
celiac trunk, superior mesenteric artery, and renal arteries
[52]. It is hypothesized that this occurs due to the diffuse
nature of the xantogranulomatous process affecting the
vessels. Lesion associated arterial stenosis was reported
regarding the abdominal aorta, celiac trunk, superior
mesenteric artery and left renal artery. Hence, vascular
involvement in ECD may lead to dire clinical consequences,
particularly when arterial stenosis is involved. Such conse-
quences may include cerebral ischemia due to carotid
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volvement, mesenteric ischemia due to superior mesenteric
artery involvement and renovascular hypertension due to
ostial stenosis of renal arteries [52]. Renovascular hyperten-
sion usually resolves pursuant angioplasty and stenting of
the stenotic renal artery. Coronary artery involvement has
been occasionally reported in the medical literature. In one
such case, a transmural involvement of all three coronary
arteries was noted. In these arteries, the lumen was severely
stenosed or obliterated by a yellowish white intimal plaque.
This plaque was laden with the typical ECD CD68(+) CD1a
(−) histiocytes [59]. ECD associated venous involvement
is much less common. Corresponding anecdotal cases
describe deep vein thrombosis, pulmonary embolism,
sagittal sinus thrombosis and obstruction of the superior
vena cava [52]. Involvement of the coronary sinus was also
noted [52].
Pulmonary involvement
A definite diagnosis of pulmonary ECD relies on the
detection of typical histiocytic infiltrates in the lung.
ECD associated pulmonary involvement was reported
to occur in 43% of the patients reviewed by Arnaud et al.
[1]. ECD is a cause of interstitial lung disease [60]. Thus,
pulmonary ECD is considered highly probable when
identifying the radiological hallmarks of interstitial lung
disease in ECD patients. The differential diagnosis of ECD
associated interstitial lung disease includes usual interstitial
pneumonia, pulmonary Langerhans' cell histiocytosis,
diffuse pulmonary Rosai Dorfman disease [61], pulmonary
lymphangitic carcinomatosis [62], pulmonary malakoplakia
and Hermansky-Pudlak syndrome [34]. The detection of
CD68(+), CD1a(−) histiocytes in bronchoalveolar lavage
fluid confirms the diagnosis of pulmonary ECD [26]. Com-
mon symptoms of pulmonary ECD include a dry cough
and insidious dyspnea which progresses over a period of
months to years [61]. Cyanosis is less frequently described.
Pulmonary function tests in patients with ECD typically
show a mild restrictive ventilation pattern with normal or
reduced carbon monoxide diffusion capacity [34]. Arterial
blood gas values are usually normal [26]. Nevertheless,
hypoxia and hyper- or hypocapnia may occur due to dis-
ease progression [34]. Arnaud and colleagues researched
the pulmonary manifestations of ECD in their retrospect-
ive analysis of 34 ECD patients. They reported that high
resolution CT findings associated with ECD involve the
lung's parenchyma and/or pleura. These findings include
interlobular septal thickening, centrilobular micronodular
opacities, thickening of the interlobar fissures, parenchyma
consolidations, microcystic lesions, thin wall cysts, pleural
effusion and pleural thickening. The histiocytic infiltration
in cases of pulmonary ECD seem to follow a lymphangitic
distribution pattern, affecting the visceral pleura, interlobu-
lar septa and around the bronchoalveolar bundles. Thispattern is usually accompanied by fibrosis, hypothesized
to be associated with the activity of factor XIIIa positive
dendritic cells. Most interestingly, these cells are abundant
in the connective tissue relating to sites of the lymphangitic
distribution discussed above [61]. Several studies reported
that pulmonary lesions in ECD exhibit immunopositivity
for factor XIIIa [11,61]. Extensive infiltration and fibrosis of
the lungs may instigate severe cardiopulmonary symptoms,
consequently, leading to cardiorespiratory failure [61].
However, in the absence of extensive pulmonary involve-
ment, these symptoms may arise secondary to cardiac
involvement promoting cardiogenic pulmonary edema
[26]. Inspection of the caliber of the pulmonary veins may
reveal whether the cause of cardiopulmonary compromise
is of pulmonary or cardiac origin: a normal caliber would
likely indicate a pulmonary cause and an extended caliber -
a cardiac cause. Despite all of the above, in a study
performed by Arnaud et al., the researchers concluded
that pulmonary involvement of ECD has a limited impact
on the overall prognosis of the disease [26].
Retroperitoneal and renal involvement
The retroperitoneal space is one of the target destinations
of histiocytic infiltration in ECD. We already discussed the
perivascular infiltration affecting the abdominal aorta. The
appearance of a "coated aorta" on CT may often appear in
conjunction with infiltration and fibrosis of lower retro-
peritoneal structures, namely the adrenal glands, kidneys,
renal arteries, ureters and adjacent anatomical spaces
and borders [52]. Overall, ECD associated involvement
of the retroperitoneal space was reported in 68% of the
patients [1]. The majority of cases in which retroperitoneal
involvement appears are asymptomatic [63]. The differen-
tial diagnosis of ECD associated retroperitoneal fibrosis
includes idiopathic retroperitoneal fibrosis (also known as
Ormonds' disease) and secondary retroperitoneal fibrosis
[25,64]. When present, the symptoms are dysuria and
abdominal pain. Large palpable kidneys may be detectable
on physical examination [63]. Infiltration of the perirenal
fat appears as an irregular renal border producing a
"hairy kidney" appearance on CT. This finding undergoes
enhancement after the administration of iodinated contrast
material and can thus be differentiated from the kidney
itself [65]. A massive infiltration of the perirenal space was
reported by Wimpissinger et al., presumably compressing
the kidneys and causing progressive renal failure. This
condition was successfully alleviated by an open surgical
approach, aimed at reducing the amount of tissue encap-
sulating the kidney and relieving pressure [66]. Perirenal
infiltration may progress to the renal sinuses and produce
a post renal obstruction. The infiltrates and subsequent
fibrosis may also cause bilateral ureteric obstruction
resulting in hydronephrosis and compromise of renal
function. The ureteral segments which are most commonly
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[25]. As previously mentioned, the renal arteries may also
be subjected to infiltration and fibrosis. Stenosis of the
renal arteries, causing decreased renal perfusion will con-
sequently instigate a state of renovascular hypertension
via a renin-angiotensin mediated pathway. CT in conjunc-
tion with angiography proves as a valuable tool in the
assessment of ECD related perivascular fibrosis [63].
Infiltration of the adrenal glands and fossae appears in
the vast majority of patients with a multisystemic disease.
It is predominantly bilateral in nature, although unilateral
adrenal infiltration has been reported. In a case series of 7
patients reviewed by Haroche and colleagues one patient
was found to experience adrenal insufficiency due to ECD
related adrenal involvement [67].Exceptional sites of involvement
Involvement of the skin [4,5,68], gastrointestinal tract
[69-71], testes [72], thyroid [72], skeletal muscle [73] and
breast [74,75] were anecdotally reported. Involvement of
the skin seems to be the most common among the rare
presentations of ECD. In the retrospective study performed
by Veyssier-Belot, 11 out of 59 patients presented with
ECD associated cutaneous involvement [5]. Among the
most common dermatological presentations of ECD are
xanthoma like papules [68] and periorbital xanthelasma
like skin lesions [4,44,61].Laboratory findings in ECD
Laboratory findings in ECD are non specific, non diagnostic
and may serve to complement the backbone of radiological
and histological findings. These are usually intertwined with
the general symptoms of the disease and when apparent,
they also may serve as means of evaluating the patient's
well being and provide gross assessment of the patient's
response to treatment. Laboratory findings of various ECD
patients may include elevated erythrocyte sedimentation
rates (ESR), increased levels of alkaline phosphatase and
increased levels of C-reactive protein (CRP) [5,9,28].
More specific laboratory findings are used for the as-
sessment of various physiological functions affected by
multisystemic ECD and could better direct towards
comprehensively understanding the patient's distribution
of the disease. Within the settings of ECD, elevated serum
creatinine and uric acid are suggestive of renal involve-
ment. Increased levels of prolactin alongside decreased
levels of LH, FSH, ACTH, GH, TSH and alteration of
other hypothalamic-pituitary axis associated hormones are
suggestive of ECD related pituitary insufficiency. Elevated
serum osmolality in conjunction with appropriate water
deprivation test results are suggestive of ECD associated
diabetes insipidus [13].Imaging studies and radiology: initial diagnosis
vs. follow-up
The initial step towards a diagnosis of ECD is either 99mTc
bone scintigraphy [76] and\or radiography findings that
are virtually pathognomonic to the disease. Conventional
radiography usually demonstrates cortical thickening
with a reduced corticomedullary cavity and scintigraphy
exhibits increased tracer uptake: both highlighting the
symmetric bilateral diametaphyseal osteosclerosis [30]. Yet,
considering that most patients have multiple (skeletal
and extraskeletal) sites of involvement at presentation [4]
follow-up imaging presents with a more complex problem:
performing a panoramic assessment of the progression of
multifocal lesions. None of the common imaging modal-
ities that are used in ECD (i.e., radiography, 99mTc bone
scintigraphy, computed tomography (CT) and magnetic
resonance imaging (MRI)) is able to provide a global
assessment of the lesions during a single session [77].
Arnaud et al. researched the application of PET scans in
ECD and concluded that PET scan assessments of osseous
involvement reveals typical bilateral and symmetric
uptake of FDG in the long bones similar to that observed
with 99mTc bone scintigraphy. Furthermore, they concluded
that a whole-body PET scan is able to depict simultaneously
many of the most relevant lesions encountered among
ECD patients. After thoroughly reviewing 31 cases of ECD
in their retrospective study, Arnaud et al. reported that
PET scan sensitivity varies greatly among the different
sites of involvement studied, but shows excellent specifi-
city when compared with most other imaging modalities.
Thus, suggesting that PET-CT is the best modality during
follow-up of the disease [77]. PET-CT also serves as a
valuable tool in the initial steps of diagnosis: it may assist
in assessing the bone marrow involvement of the patient
and identify candidate areas for CT guided percutaneous
biopsy when extraskeletal involvement seems prominent
[28]. High risk infiltration sites should be routinely moni-
tored in ECD. MRI is the modality of choice when evaluat-
ing the different CNS manifestations. MRI should be used
for the overall assessment of cerebral and cerebellar lesions,
the hypothalamic pituitary axis and the orbits [10]. The
efficacy of whole body MRI has not yet been fully evaluated,
yet preliminary results seem promising [78]. CT comple-
ments the MRI findings by adding data concerning the
involvement of the skull bones and sinuses. After
researching the aspects of cranial imaging in ECD patients,
Drier et al. recommend to systematically perform cerebral
MRI on ECD patients. This is due to the severity of poten-
tial progression and risks associated with perivascular
lesions and intracranial vascular stenosis [10]. Cardiac
and mediastinal infiltrations are assessed primarily using
contrast enhanced CT. Moreover, cardiac gated multi-
detector CT can better demonstrate the infiltrate sheathing
of the aortic root and proximal portions of the coronary
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Echogradiography can add valuable data concerning the
extent of cardiac involvement and of pericardial effusion in
particular [49]. Both CT and MRI are useful tools for the
assessment of the thoracoabdominal involvements of ECD.
Retroperitoneal involvement, periaortic ("coated aorta")
and perirenal ("hairy kidney") in particular can be observed
on both enhanced and unenhanced CT scans. These can be
complemented by angiography studies for the evaluation of
possible stenosis due to perivascular infiltration, a possible
complication of renal artery involvement. A multi-detector
CT scan can be used for better representation of the renal
pelvises, enabling detection of distal ureteral obstructions
and hydronephrosis [65]. Renal duplex ultrasound is
another option for an assessment of the renal arteries and
ureters and may also assist in gross kidney measurements
[63]. Retrograde pyelography can be used preoperatively
to assess the compression on the urinary tract [66].
Pulmonary assessment includes high resolution CT for
the detection of lung or pleural involvement. Arnaud et al.
suggest using high resolution CT at the time of diagnosis,
during initial assessment and later on if pulmonary symp-
toms occur. If necessary, this should be done in conjunction
with an annual assessment using a low dose CT of the
chest, abdomen and pelvis, closely examining the lung win-
dow for ECD associated pulmonary findings [26]. Rarer
breast involvement can be seen on mammography [75].
Pathology
In order to finalize a diagnosis of ECD, a histopathological
confirmation is necessary. A biopsy is usually obtained
from bone, skin, retro-orbital or retroperitoneal soft tissue
[13]. Confirmation is made upon detection of CD68(+),
CD1a(−) non Langerhans histiocytes with foamy or
eosinophillic cytoplasm lacking Birbeck granules. These
are usually accompanied by a microscopic environment
including polymorphic granulomae, fibrosis, xanthogra-
nulomatosis, proliferating fibroblasts, lymphocytic aggre-
gates and Touton giant cells.
Pathogenesis of ECD
The CD34(+) myeloid stem cell gives rise to three lineages
of histiocytic and dendritic cells [27]. While Langerhans'
cell histiocytosis exhibits the proliferation of CD1a(+),
Langerin(+), S100(+) Langerhans' dendritic cells, ECD
is hypothesized to originate from the proliferation and
migration of CD68(+), CD1a(−) non Langerhans' histiocytes
of monocyte-macrophage descent. Discussions concerning
the interplay between Langerhans' cell histiocytosis and
ECD in face of patients with both diseases yielded no
conclusive answers. Some researchers hypothesized that
the existence of patients with both diseases is attributed to
an unknown abnormality or dysfunction of the CD34(+)
progenitor cell. ECD differs from Langerhans' cellhistiocytosis by the immunohistologic and microscopic
characteristics of the histiocytes involved. Langerhans-like
histiocytes stain positive for S-100 protein, and electron
microscopy of their cytoplasm discloses Birbeck granules
in more than 20% of cells [79]. ECD histiocytes have
neither of these characteristics [5]. However, cases in
which S-100 expression was positive were observed in
the literature [61]. The typical histological appearance
of ECD consists of CD68(+), CD1a(−), S-100(−/low)
non langerhans cell histiocytes. Moreover, Factor XIIIa
was found to be positive in ECD lesions derived from
pulmonary origin [61]. The microscopic environment of
the lesion includes xanthogranulomatosis, proliferating
fibroblasts (generating fibrosis), lack of eosinophils,
lymphocytic aggregates and Touton giant cells [13,26,37].
Recent studies attempted to elucidate the pathogenesis of
ECD. It is currently unknown whether ECD is a monoclo-
nal neoplastic process or a polyclonal reactive process.
Several researchers attempted to provide a solid answer to
that question, some utilizing human androgen receptor
gene assays (HUMARA) and some searching for cytogen-
etic clonal abnormalities [21,80-82]. Alas, due to conflicting
data, no definite answer was found. A different approach
proved more fruitful. A recent study of 37 patients by
Arnaud et al. identified a cytokine\chemokine profile
unique to ECD, consisting of increased levels of interferon-
α, interleukin-12, monocyte chemotactic protein-1 (MCP1/
CCL2) and decreased levels of interleukins 4 and 7. This
profile is constant despite treatment with interferon-α,
suggesting that interferon-α has a limited role in altering
the cytokine network at hand. Most interestingly, both
interferon-α treated and untreated patients exhibited high
levels of interferon-α. Moreover, the paradoxical high levels
of interferon-α seem to originate from an unknown source,
as no interferon-α secreting dendritic cells were identified
in ECD lesions. However, the lesions stained positive for
interferon-γ. Intralesional interferon-γ positive lymphocytes
and the detection of interferon-γ inducible protein 10
(OP-10) expressed by histiocytes provided evidence that
ECD is characterized by a strong Th1 immune response
[83]. Stoppacciaro et al. also reviewed chemokine and
cytokine levels in three ECD patients. They reported an
increased expression of chemokines and their correspond-
ing receptors in ECD histiocytes and in epithelial cells of
vessels inside the lesions. Also, they reported that Ki-67
staining was undetectable and that no mitotic figures were
seen adding evidence against a mechanism of intra-lesional
histiocytic proliferation. Evidence of a Th1 immune
response also appears in this study as high levels of
interferon-γ with low levels of interleukin-10 were reported
[84]. Several studies indicated increased levels of TNFα
[85], interleukin-6 [86] and normal to high levels of
interleukin-1β [9,83,87,88]. Future studies are needed to
assess the importance of these cytokines as therapeutic
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were treated with infliximab and anakinra based on these
therapeutic targets showed optimistic results. Finally,
recent data points to a high prevalence of BRAF V600E
mutations among ECD and LCH patients [18,89] advocating
the possible usage of BRAF inhibitors such as vemurafenib
in the targeted treatment of ECD.
Treatment
To this date, various treatments have been administered
to ECD patients in an attempt to achieve remission or at
least stabilization. Several approaches based on diverse
biological theories and small scale clinical experience
have been proposed. Currently, interferon-α provides the
best management strategy, with sustainable stabilization
of the disease in most cases, [1,12,90,91]. Interferon-α isTable 2 Profile of the ECD patient
Age at onset 5th - 7th decade of life
Presenting symptoms Diabetes insipidus, bone pain and e
Disease distribution Skeleton: Long bones osteoscleros
Cranium & CNS:




Pericardial infiltration / effusion
Periaortic sheathing ("coated aorta"





Perirenal infiltration ("hairy kidney")
Post renal obstruction (hydronephr
Renal artery stenosis (renovascular
Cutaneous: Periorbital xanthelasma
Imaging 99mTc Bone Scintigraphy
PET/CT
Treatment 1st line alternatives:






Prognosis 1 year survival: 96%
5 year survival: 68%
(*) may be advocated as a first line treatment modality among some specialists.administered at dosages ranging from 3 million units
three times per week to 9 million units 3 times per week.
Peginterferon alfa-2a, the pegylated form of interferon-α, is
an equivalent alternative to interferon-α. It is administered
at dosages ranging from 135–200 μg per week [1]. It must
be taken into consideration that treatment with these
agents is prolonged. Thus, tolerance to treatment should
be considered pivotal in long term treatment planning.
Among the adverse effects of interferon-α are asthenia,
myalgia, pruritus, thrombocytopenia and depression [92].
The efficacy of interferon-α varies in concordance with the
different sites of disease involvement. One recent large
survey encompassing 24 patients treated with high dose
interferon-α (>18 million units per week) or high dose
peginterferon alfa-2a (>185 μg per week) reported them to
be efficacious in the treatment of patients with severeArnaud et al. [1]
xophthalmos Veyssier-Belot [5]
is (bone pain) Dion et al. [30]
Drier et al. [10]
, panhypopituitirism)
)
Haroche et al. [54]
)
umor
Arnaud et al. [26]




Gotthardt et al. [76]
Arnaud et al. [77]
Arnaud et al. [1]
Hervier et al. [92]
Myra et al. [93], Adam et al. [103]
Haroche et al. [101]
Aouba et al. [88]
Dagna et al. [85]
Arnaud et al. [1]
Mazor et al. Orphanet Journal of Rare Diseases 2013, 8:137 Page 10 of 13
http://www.ojrd.com/content/8/1/137ECD. The response to treatment was most prominent in
the cutaneus foci of the disease, followed by involvement
of the CNS, pituitary, lungs and heart, which comprise foci
that are more resistant to treatment [92]. Several smaller
reports corroborate the efficacy of interferon-α in respect
to other sites of the disease. Braiteh et al. report substantial
durable regression (3–4.5 years) of retro-orbital lesions, as
well as marked improvement in bone lesions, pain and
symptoms of diabetes insipidus in three patients treated
with interferon-α [90]. Arnaud et al. report interferon-α
had only a minor impact on the course of pulmonary ECD
involvement [26]. No interferon-α response predicting
factors were identified [92]. However, in a recent survey
of 53 patients, treatment with interferon-α itself was
identified as a independent predictor of survival. It is
currently the only agent that has shown to improve survival
among ECD patients [1]. Cladribine (2cda) is advocated as
an alternative treatment for ECD. However, the literature
contains significantly less data regarding this drug in
comparison to interferon-α. Cladribine is administered
at dosages ranging from 0.07-0.14 mg/kg/day for five
consecutive days. Myra et al. reported an ECD patient
who experienced marked recovery pursuant treatment with
cladribine [93]. Adam et al. reported partial regression of
CNS ECD lesions following treatment with a cladribine
based regimen [94]. As for adverse effects, cladribine may
be associated with dose dependent bone marrow suppres-
sion, and neurological toxicity. Sheidow et al. reported a
single ECD patient who developed sudden onset bilateral
blindness presumably due to cladribine related toxic injury
to the optic nerves. Corticosteroids carried the promise
of immune suppression, but proved to have a very lim-
ited impact on the disease [1,5,90]. Different types of
chemotherapy based regimens were attempted with various
degrees of success, but in most cases provided only
temporary relief [5,44,93,95]. Radiation therapy fails to yield
a sustainable clinical response [90]. Surgical debulking may
provide a temporary solution for specific compromising
scenarios, as the lesions tend to re-grow rapidly [13].
Inhibition of PDGF signaling using imatinib or sunitinib
yielded modest results at best [26,48,96]. Treatment with
bisphosphonates produces only partial success in the
management of osseous involvement [86,97,98]. Recent
advancements in the understanding of the molecular
biology of ECD presented with new promising treatment
options. Encouraging results accumulate regarding the
targeting of interleukin-1 (Anakinra) [9,88,99,100]. One
other promising pharmaceutical agent is the BRAF inhibi-
tor vemurafenib, which recently exhibited dramatic efficacy
in the treatment of three ECD patients whose histiocytes
were positive for the V600E BRAF mutation [101]. Finally,
other possibilities based on the immunological basis of
ECD include anti interleukin-6 therapy (Tocilizumab)
and anti TNFα therapy (Infliximab) [85,102].Summary and future perspectives
Herein we have gathered a fair share of the scientific
knowledge regarding ECD. A synopsis of the core data
can be found in Table 2. As an orphan multi-systemic
disease both diagnosis and treatment are challenging.
Diagnosis wise, the challenge is lesser and requires a
high degree of suspicion. Treatment and management of
the disease are of greater complexity. Since no definite
cure exists, the goals of treatment should be prolonging
life and maximizing their quality. Psychological consulting
is important because success of the physical treatment
usually results in the maintenance of a chronic condition.
As such, it may be accompanied by various difficulties,
deficits and secondary complications. The physical com-
ponent of treatment should be supervised by a multidis-
ciplinary team of specialists, whose expertise should
correlate with the patient's distribution of the disease.
Secondary intervention and treatment modifications should
be made based on proper assessment of the disease's
progression as well as the patient’s well being. With time,
better understanding of the immunology and molecular
biology that underlie this condition will ultimately lead to
the emergence of novel therapeutic approaches. Already,
much progress had been made in identifying disease re-
lated elements which may prove pivotal for future man-
agement. One such example is the identification of the
cytokine network patterns that characterizes ECD and
consequently, the possibility of treatment via a mechanism
of pro-inflammatory cytokine inhibition. Another example
is the identification of mutated cellular components which
may be responsible for the proliferation and differentiation
of ECD histiocytes. Possibly, such is the case of the V600E
BRAF mutation and vemurafenib.
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